Abstract
We report our continued experience with rifaximin as a post-vancomycin treatment strategy in six patients with multiple recurrences of C. difficile infection (CDI). Four of the six patients (67%) had no further diarrhea episodes, but two patients failed shortly after or during the rifaximin treatment. C. difficile isolates from one of the two patients who failed treatment had an MIC of >256 microg/ml to rifampin. Serial therapy with vancomycin, followed by rifaximin remains an option for some patients with multiple CDI recurrences.
Publication types
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Anti-Bacterial Agents* / administration & dosage
-
Anti-Bacterial Agents* / pharmacology
-
Anti-Bacterial Agents* / therapeutic use
-
Clostridioides difficile / drug effects*
-
Clostridium Infections / drug therapy*
-
Clostridium Infections / prevention & control
-
Drug Therapy, Combination
-
Enterocolitis, Pseudomembranous / drug therapy*
-
Enterocolitis, Pseudomembranous / prevention & control
-
Female
-
Gastrointestinal Agents* / administration & dosage
-
Gastrointestinal Agents* / pharmacology
-
Gastrointestinal Agents* / therapeutic use
-
Humans
-
Male
-
Microbial Sensitivity Tests
-
Rifamycins* / administration & dosage
-
Rifamycins* / pharmacology
-
Rifamycins* / therapeutic use
-
Rifaximin
-
Secondary Prevention
-
Treatment Outcome
-
Vancomycin* / pharmacology
-
Vancomycin* / therapeutic use
Substances
-
Anti-Bacterial Agents
-
Gastrointestinal Agents
-
Rifamycins
-
Vancomycin
-
Rifaximin